

Appl. No. 10/764,177  
Amendment dated: September 5, 2006

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (original) An enveloped pharmaceutical composition comprising:  
a first active available for immediate release; and  
a second active for extended release selected from the group consisting of a decongestant, an antihistamine, an expectorant, an antitussive and mixtures thereof, wherein the first and the second active are disposed on separate carriers.
2. Cancelled
3. Cancelled
4. (currently amended) The composition of claim 1, wherein the first and second actives are packed into ~~a capsule, caplet, softgel, gelcap, suppository, film, granule, gum, insert, pastille, pellet, troche, lozenge, disk, poultice or wafer~~ a capsule, a suppository, a gel cap, a softgel, a lozenge, a sachet or a fast dissolving wafer.
5. (original) The composition of claim 1, wherein over 80% of the first active is released within about 60 minutes.
6. (original) The composition of claim 1, wherein immediate release is defined further as comprising release of over 90% of the first active within about 90 minutes.
7. (original) The composition of claim 1, wherein extended release is defined further as comprising release of over 80% of the second active within about 60 minutes to about 8 hours.
8. (original) The composition of claim 1, wherein extended release is defined further as comprising release of over 90% of the second active within about 90 minutes to about 6 hours.
9. (currently amended) The composition of claim 1, wherein the first active comprises ~~guaifenesin~~ guaifenesin.
10. (currently amended) The composition of claim 1, wherein the first active comprises ~~guaifenesin~~ guaifenesin DC in a powder form.

Appl. No. 10/764,177

Amendment dated: September 5, 2006

11. (currently amended) The composition of claim 1, wherein the first active comprises 211 mg of 95% ~~gauifenesin~~ guaifenesin.
12. (original) The composition of claim 1, wherein the second active comprises a nasal decongestant.
13. (original) The composition of claim 1, wherein the second active comprises phenylephrine.
14. (original) The composition of claim 1, wherein the second active comprises phenylephrine as a sustained release bead.
15. (original) The composition of claim 1, wherein the second active comprises phenylephrine as a layered sustained release bead.
16. (original) The composition of claim 1, wherein the second active comprises three or more layers of phenylephrine on a bead.
17. (original) The composition of claim 1, wherein the first active is superposed on the second active.
18. (original) The composition of claim 1, comprising further one or more inactives.
19. (original) The composition of claim 1, wherein the first active for immediate release comprises a powder form and the second active comprises a beaded form.
20. (original) An enveloped pharmaceutical composition comprising:  
a first active available for immediate release; and  
a second active available for extended release, wherein the first active effects a physiological result that improves the physiological action of the second active upon extended release.
21. (original) The composition of claim 20, wherein the first and second actives are enveloped in a single dose.
22. (original) The composition of claim 20, wherein the first and second actives are enveloped into a single dose.
23. (currently amended) The composition of claim 20, wherein the first and second actives are packed into ~~a capsule, caplet, softgel, gelcap, suppository, film, granule, gum, insert, pastille, pellet, troche, lozenge, disk, poultice or wafer~~ a capsule, a suppository, a gel cap, a softgel, a

Appl. No. 10/764,177

Amendment dated: September 5, 2006

lozenge, a sachet or a fast dissolving wafer.

24. (original) The composition of claim 20, wherein over 80% of the first active is released within about 60 minutes.
25. (original) The composition of claim 20, wherein immediate release is defined further as comprising release of over 90% of the first active within about 90 minutes.
26. (original) The composition of claim 20, wherein extended release is defined further as comprising release of over 80% of the second active within about 60 minutes to about 8 hours.
27. (original) The composition of claim 20, wherein extended release is defined further as comprising release of over 90% of the second active within about 90 minutes to about 6 hours.
28. (original) The composition of claim 20, wherein the second active for extended release is selected from the group consisting of a decongestant, an antihistamine, an expectorant, an antitussive and mixtures thereof.
29. (currently amended) The composition of claim 20, wherein the first active comprises ~~gauifenesin~~ guaifenesin.
30. (currently amended) The composition of claim 20, wherein the first active comprises ~~Gauifenesin~~ Guaifenesin DC in a powder form.
31. (currently amended) The composition of claim 20, wherein the first active comprises 211 mg of 95% ~~gauifenesin~~ guaifenesin.
32. (original) The composition of claim 20, wherein the second active comprises a nasal decongestant.
33. (original) The composition of claim 20, wherein the second active comprises phenylephrine.
34. (original) The composition of claim 20, wherein the second active comprises phenylephrine as a sustained release bead.
35. (original) The composition of claim 20, wherein the second active comprises phenylephrine as a layered sustained release bead.
36. (original) The composition of claim 20, wherein the second active comprises three or more layers of phenylephrine on a bead.

Appl. No. 10/764,177

Amendment dated: September 5, 2006

37. (original) The composition of claim 20, wherein the first active is superposed on the second active.
38. (original) The composition of claim 20, comprising further one or more inactives.
39. (original) The composition of claim 20, wherein the first active for immediate release comprises a powder form and the second active comprises a beaded form.
40. (original) An enveloped pharmaceutical composition comprising:  
a first active packaged so that over 90 % of the first active is released within about 90 minutes;  
and  
a second active for extended release selected from the group consisting of a decongestant, an antihistamine, an expectorant, an antitussive and mixtures thereof, wherein over 90% of the second active is released between about 1 and 6 hours.
41. (original) The composition of claim 40, wherein the first and the second actives are disposed on separate carriers.
42. (original) The composition of claim 40, wherein the first and second actives are enveloped in a single dose.
43. (original) The composition of claim 40, wherein the first and second actives are enveloped into a single dose.
44. (currently amended) The composition of claim 40, wherein the first and second actives are packed into ~~a capsule, caplet, softgel, gelee, suppository, film, granule, gum, insert, pastille, pellet, troche, lozenge, disk, poultice or wafer~~ a capsule, a suppository, a gel cap, a softgel, a lozenge, a sachet or a fast dissolving wafer.
45. (original) The composition of claim 40, wherein over 80% of the first active is released within about 60 minutes.
46. (original) The composition of claim 40, wherein immediate release is defined further as comprising release of over 90% of the first active within about 60 minutes.
47. (original) The composition of claim 40, wherein extended release is defined further as comprising release of over 80% of the second active within about 60 minutes to about 8 hours.

Appl. No. 10/764,177

Amendment dated: September 5, 2006

48. (original) The composition of claim 40, wherein extended release is defined further as comprising release of over 90% of the second active within about 90 minutes to about 6 hours.
49. (currently amended) The composition of claim 40, wherein the first active comprises ~~gauifenesin~~ guaifenesin.
50. (currently amended) The composition of claim 40, wherein the first active comprises ~~gauifenesin~~ guaifenesin in a powder form.
51. (currently amended) The composition of claim 40, wherein the first active comprises 211 mg of 95% ~~gauifenesin~~ guaifenesin.
52. (original) The composition of claim 40, wherein the second active comprises a nasal decongestant.
53. (original) The composition of claim 40, wherein the second active comprises phenylephrine.
54. (original) The composition of claim 40, wherein the second active comprises phenylephrine as a sustained release bead.
55. (original) The composition of claim 40, wherein the second active comprises phenylephrine as a layered sustained release bead.
56. (original) The composition of claim 40, wherein the second active comprises three or more layers of phenylephrine on a bead.
57. (original) The composition of claim 40, wherein the first active is superposed on the second active.
58. (original) The composition of claim 40, comprising further one or more inactives.
59. (original) The composition of claim 40, wherein the first active for immediate release comprises a powder form and the second active comprises a beaded form.
60. (Currently amended) An enveloped pharmaceutical composition comprising:  
a first active available for immediate effervescent release; and  
a second active in a mini-tab for extended release ~~in a mini-tab~~ selected from the group consisting of a decongestant, an antihistamine, an expectorant, an antitussive and mixtures thereof.

Appl. No. 10/764,177

Amendment dated: September 5, 2006

61. (Currently amended) An enveloped pharmaceutical composition comprising:  
a first active available for immediate release; and  
a second active for extended release on a carrier selected from the group consisting of a decongestant, an antihistamine, an expectorant, an antitussive and mixtures thereof wherein the first and second actives are different.

62 – 80 cancelled.